The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The conversation discusses using oral Minoxidil, topical Minoxidil with RU58841, Finasteride, and serioxyl for hair loss. It also asks for opinions on the effectiveness of other treatments like Setipiprant, Dutasteride, and Spironolactone, and thoughts on HMI-115 and GT20029 trials.
The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.
The conversation is about the role of vitamin deficiencies in hair loss and the effectiveness of treatments like Minoxidil, finasteride, and RU58841. It concludes that while vitamins and nutrition are important, they are not the primary solution for androgenic alopecia.
The conversation provides scientific sources on hair loss treatments like finasteride, minoxidil, and others, aiming to help individuals make informed decisions about their treatment options. It also discusses phytochemicals as alternative treatments due to concerns about side effects from drug-based therapies.
Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.
People regret not starting hair loss treatments like Minoxidil and Finasteride earlier, as they've lost significant hair by waiting. Some experienced side effects like itchy nipples or increased libido, but overall, they wish they had acted sooner to prevent hair loss.
The conversation discusses Kevin's accurate information on hair loss treatments and highlights Dr. Bloxham's ongoing work with Verteporfin on FUT scars, suggesting people follow Dr. Bloxham's YouTube for updates. It also thanks Haicafe and Melvin from the hair restoration network forum for their contributions.
The conversation discusses using Nizoral 2% for hair loss treatment without having dandruff, with advice on allowing it to absorb for 10 minutes before rinsing and a personal experience of the product causing dry and itchy scalp.
The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.
The user switched from finasteride to dutasteride for hair loss treatment, but experienced increased libido, itchy scalp, and accelerated hair loss. Another user suggested that genetic variations might cause dutasteride to be less effective and recommended checking for specific genetic markers.
A user's 8-month progress on finasteride for hair loss treatment, with plans to continue for a full year. The user experienced initial shedding and scalp itch, which subsided, leading to hair growth. Other users discussed the necessity of continuous treatment to maintain results.
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.
The conversation is about a 53-year-old man's struggle with hair loss and the various perspectives on balding. It also mentions the use of finasteride as a hair loss treatment.
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
The conversation discusses hair loss and specific treatments like Minoxidil, Finasteride, and RU58841. It also highlights Procyanidin B-2 as a secret ingredient for hair growth.
The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.
The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.
The conversation is about the effectiveness of ketoconazole shampoo for hair loss. The conclusion is that ketoconazole shampoo can help with dandruff and seborrheic dermatitis, but it is not a strong enough treatment to stop or regrow hair. It is recommended to use it as an adjunct treatment along with finasteride or dutasteride.
The conclusion of the conversation is that oral minoxidil has been effective in saving and restoring hair, but it may have diminishing returns as you age. It is suggested to consider using finasteride in addition to minoxidil for better results.
The conversation provides advice on how to track hair loss or regrowth, emphasizing the importance of taking consistent photos and keeping a log of treatments like minoxidil and finasteride. It also suggests using scalp cameras and comparing photos side by side for accurate progress assessment.
The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.
The conclusion of the conversation is that some users have seen positive results with the use of finasteride and minoxidil for hair loss, while others have not. It is mentioned that consistent use of these treatments is necessary to maintain results.
The conversation is about a user experiencing excessive hair growth on their body due to using topical minoxidil and dutasteride. The suggested solutions are shaving off the excess hair or considering laser epilation. It is mentioned that dutasteride does not cause extra hair growth, while minoxidil can stimulate hair growth in unintended areas. The user is advised to lower the dosage, concentration, or frequency of use and only apply the treatment to the desired areas.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.